Jersey has witnessed a significant rise in cannabis use since the island legalized medicinal cannabis in 2019, a development that has sparked growing concerns over a related mental health crisis. Currently, about one in 25 islanders are reported to be using cannabis products, which are prescribed to treat a wide range of conditions including anxiety, ADHD, insomnia, and chronic pain.
The cost of a typical cannabis prescription on Jersey varies widely, ranging from £70 to £400 per month depending on dosage and product type. Despite the National Health Service (NHS) stating that cannabis products only benefit a small number of patients, prescriptions have become increasingly common on the island. Cannabis contains numerous compounds, but tetrahydrocannabinol (THC) is the psychoactive element, with dosages usually varying between 2 mg and 25 mg.
Several residents credit medicinal cannabis with significantly improving their quality of life. Alison Fromager, 54, who suffers from multiple chronic conditions including debilitating pain and fatigue, described how cannabis oils reduced her reliance on pharmaceutical drugs from 15 tablets a day to just one alongside the oils. Although she tried smoking cannabis and consuming edibles, she found oils to be the most manageable and effective form to alleviate her symptoms and associated anxiety.
Similarly, other users have reported positive outcomes, with one resident turning to cannabis vaping to manage insomnia after prescriptions for sleeping pills were stopped. James Bedding, a quadriplegic following an accident at age 15, credits cannabis vaping with relieving severe muscle spasms and enabling him to resume work. Bedding, who consumes around 5 grams of cannabis daily, has also opened a vape shop in St Helier, the island’s capital.
However, concerns about the rise in recreational and medicinal cannabis use have prompted calls for stronger regulation. Deputy Karen Wilson, Jersey’s former health minister and a mental health professional, has cautioned about the risks of cannabis exacerbating anxiety and psychosis, citing cases where elderly patients developed severe mental health issues after receiving cannabis prescriptions. She has criticized the aggressive marketing of cannabis products and noted that some doctors have been financially incentivized to prescribe the drug, contributing to its widespread availability.
Her successor, Health Minister Tom Binet, has acknowledged the need for tightened controls and plans to introduce regulations requiring cannabis clinics to conduct comprehensive medical assessments, hold face-to-face consultations, and monitor adverse reactions. Critics argue these measures should have been implemented from the outset.
Earlier this year, Sir Robin Murray, an expert affiliated with the UK Advisory Council on the Misuse of Drugs, described Jersey’s approach to cannabis regulation as “cavalier,” warning that commercial interests appear to be prioritized over patient welfare. Binet emphasized the government’s responsibility to protect public interest and ensure that profit motives do not undermine health safeguards.
The island faces a complex challenge balancing the claims of individuals who find relief in medicinal cannabis against mounting evidence of mental health harms. While the legalization of cannabis was initially hailed as progressive, the growing demand for mental health support related to its use suggests that Jersey is still grappling with the full implications of the policy shift.